MedTrace Logo

Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1

NCT00015171 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2017-01-16

No results posted yet for this study

Summary

The purpose of this study is the use of buprenorphine/naloxone in treatment of opioid dependence.

Conditions

  • Heroin Dependence
  • Substance-Related Disorders

Interventions

DRUG

Buprenorphine/naloxone

Sponsors & Collaborators

  • New York MDRU

    collaborator OTHER

  • National Institute on Drug Abuse (NIDA)

    lead NIH

Principal Investigators

  • John Rotrosen, M.D. · New York MDRU

Study Design

Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-04-30
Primary Completion
1997-05-31
Completion
1997-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00015171 on ClinicalTrials.gov